<DOC>
	<DOCNO>NCT00324571</DOCNO>
	<brief_summary>This randomize , open-label , parallel-design study conduct 75 center within United States . The study describe hemodialysis patient . Informed consent obtain inclusion/exclusion criterion review . Eligible patient randomize receive either Renagel calcium-based binder . Starting randomization date , mortality data include survival , death date cause death ( vital status information ) morbidity data include hospitalization date record patient . These data collect end study ( December 31 , 2004 , Â± 2 week ) . Patients complete terminate study return phosphate binder prescribe usual healthcare provider .</brief_summary>
	<brief_title>Dialysis Clinical Outcomes Revisited ( DCOR ) Trial</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>patient must 18 year age old , dialysis 3 month , require phosphate binder therapy , Medicare primary insurance . dysphagia , swallow disorder , severe gastrointestinal motility disorder , bowel obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>